Atossa Therapeutics (ATOS) News Today → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free ATOS Stock Alerts $1.29 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAtossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirementsglobenewswire.com - March 18 at 8:30 AMATOS Apr 2024 4.000 callfinance.yahoo.com - March 16 at 9:59 AMAtossa Therapeutics adds breast cancer expert to boardproactiveinvestors.com - March 12 at 9:53 AMAtossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directorsglobenewswire.com - March 12 at 8:30 AMATOS Oct 2024 2.000 callfinance.yahoo.com - March 11 at 1:04 PMAtossa Therapeutics (NASDAQ:ATOS) Share Price Crosses Above Two Hundred Day Moving Average of $0.81americanbankingnews.com - March 9 at 3:44 AMAtossa Therapeutics to present data from ongoing Phase 2 breast cancer trialproactiveinvestors.com - March 6 at 9:24 AMAtossa Therapeutics, Inc.edition.cnn.com - February 28 at 9:51 PMAtossa Therapeutics Stock (NASDAQ:ATOS), Short Interest Reportbenzinga.com - February 24 at 9:44 AMAtossa Therapeutics, Inc.: Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Studyfinanznachrichten.de - February 22 at 1:10 PMAtossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trialproactiveinvestors.com - February 22 at 9:56 AMAtossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Studyglobenewswire.com - February 22 at 8:30 AMAtossa Therapeutics, Inc. (YAG2.SG)au.finance.yahoo.com - February 20 at 3:57 PMATOS Mar 2024 1.000 putfinance.yahoo.com - February 17 at 2:26 AMAtossa Therapeutics, Inc. (NASDAQ:ATOS) to Post FY2023 Earnings of ($0.23) Per Share, HC Wainwright Forecastsmarketbeat.com - February 14 at 7:42 AMAtossa spikes as H.C. Wainwright starts at Buy on lead assetmsn.com - February 12 at 4:52 PMHC Wainwright Initiates Coverage on Atossa Therapeutics (NASDAQ:ATOS)marketbeat.com - February 12 at 8:19 AMAtossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trialfinance.yahoo.com - February 7 at 12:00 PMAtossa Therapeutics (NASDAQ:ATOS) Stock Passes Above 200-Day Moving Average of $0.81marketbeat.com - February 6 at 3:36 AMAtossa Therapeutics progresses Phase II preventative breast cancer therapymsn.com - January 27 at 4:59 AMTraders Purchase Large Volume of Atossa Therapeutics Call Options (NASDAQ:ATOS)marketbeat.com - December 29 at 12:17 PMIs Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?finance.yahoo.com - December 8 at 1:21 PMAtossa Therapeutics taps Arezoo Mirad for Senior Medical Directorproactiveinvestors.com - December 4 at 10:35 AMAtossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Directorfinance.yahoo.com - December 4 at 10:35 AMAtossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trialfinance.yahoo.com - November 20 at 9:59 AMAtossa Therapeutics GAAP EPS of -$0.05 beats by $0.02msn.com - November 13 at 3:58 PMAtossa Therapeutics advances (Z)-endoxifen for breast cancer research program during 3Qproactiveinvestors.com - November 13 at 9:41 AMAtossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:41 AMAtossa Therapeutics’ (Z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situproactiveinvestors.com - October 30 at 6:57 PMCognito Therapeutics Appoints Greg Weaver as Chief Financial Officerfinance.yahoo.com - October 17 at 9:05 PMAtossa Therapeutics names finance lead after CFO's quick exitbizjournals.com - October 11 at 6:36 PMFast-food consumption by adolescent girls may sow the seeds of breast cancer decades laterfinance.yahoo.com - October 11 at 1:35 PMAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023finance.yahoo.com - September 18 at 10:51 AMApproximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatmentfinance.yahoo.com - September 18 at 10:51 AMCantor Fitzgerald Initiates Coverage of Atossa Therapeutics (ATOS) with Overweight Recommendationmsn.com - September 8 at 3:09 PMAtossa stock jumps 16% in wake of Cantor overweight ratingmsn.com - September 8 at 3:09 PMBreast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analystmarkets.businessinsider.com - September 8 at 3:09 PMAtossa Therapeutics: Betting Big On Transforming Old Breast Cancer Caremsn.com - August 31 at 8:27 PMAtossa Therapeutics (ATOS) Price Target Increased by 13.51% to 5.36msn.com - August 31 at 6:34 AMAtossa Therapeutics is targeting multiple stages of the breast cancer continuum with oral Endoxifenproactiveinvestors.com - August 23 at 5:34 PMAtossa Therapeutics backing Endoxifen in the fight against breast cancerfinance.yahoo.com - August 23 at 8:36 AMAtossa Therapeutics backing Endoxifen in the fight against...Atossa Therapeutics backing Endoxifen in the fight against breast...proactiveinvestors.com - August 23 at 3:35 AMAtossa Therapeutics (NASDAQ:ATOS) Research Coverage Started at StockNews.commarketbeat.com - August 17 at 2:56 AMQ2 2023 Atossa Therapeutics Inc Earnings Callfinance.yahoo.com - August 15 at 2:54 AMAtossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 14 at 8:52 AMAtossa gains as Canada greenlights breast cancer trialmsn.com - July 20 at 6:24 PMAtossa Therapeutics, Inc.: Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canadafinanznachrichten.de - July 20 at 1:24 PMAtossa Therapeutics gets green light to open enrollment for Phase 2 breast cancer trial in Canadaproactiveinvestors.com - July 20 at 1:24 PMAtossa Therapeutics regains compliance with Nasdaq's minimum bid price ruleseekingalpha.com - July 14 at 8:16 AMMaxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)markets.businessinsider.com - July 11 at 2:20 PM Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address My next big prediction isn’t a prediction (Ad)I believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in. Click here now to sign up ATOS Media Mentions By Week ATOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.410.64▲Average Medical News Sentiment ATOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼41▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NKTR News ACET News PRQR News RLMD News KPTI News GLYC News SYRE News IMRX News GTHX News RANI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.